Hello, Welcome to Shine Consultant !
Guest Information
Dr. Kevin PAN
Dr. Kevin PAN
发布时间: 2020 - 11 - 26
点击次数: 0
Positions： Founder, Chairman, CEO
Company： Asieris Pharmaceuticals
个人简介：
Dr. Kevin Pan is a co-founder of Asieris Pharmaceuticals and has served as chairman of the board and CEO since Mach 2010. Asieris is a private, VC-backed clinical-stage biotech company based in China and with clinical operations in the US. Before founding Asieris, Dr. Pan was a founding member of Hutchison MediPharma, a leading Chinese biopharmaceutical company listed on AIM and Nasdaq. He served as the senior director of drug discovery chemistry and IP at the beginning, and then led the company’s business development with a successful track record of partnership deals with P&G and Merck Serono. Dr. Pan started his career in the pharmaceutical industry from the R&D divisions at Pfizer (Groton, CT) and Johnson & Johnson (Spring House, PA).  Dr. Pan received a BS degree in organic chemistry from Fudan University in Shanghai and a Ph.D. degree in bioorganic chemistry from Rutgers, the State University of New Jersey. He had been an adjunct professor at the School of Pharmacy of Jilin University in China between 2005-2010, and he is currently members of the Bayhelix Group and Chinese Society of Clinical Oncology (CSCO).
查看详情>>
Chengbin WU
Chengbin WU
发布时间: 2020 - 11 - 26
点击次数: 0
Positions： Founder & CEO
Company： EpimAb Biotherapeutics Inc.
个人简介：
Dr. Chengbin Wu is the founder and Chief Executive Officer of EpimAb Biotherapeutics Inc., an innovative, clinical-stage biologics company focusing on developing next generation antibody-based therapies for oncology and other areas of high unmet medical needs. Dr. Wu has over 20 years of experience in discovery, development, and technological innovation in the antibody field, and he is a world renowned expert in bispecific antibody technologies and therapeutic development.  Dr. Wu has built a distinguished career in the biopharmaceutical industry, taking on different leadership responsibilities in different parts of the world.  Previously he was Chief Scientific Officer and President of R&D at Shanghai CP Guojian Pharmaceutical Co., a leading China-based biopharmaceutical company. Before that he was the Senior Vice President Biologics at Shanghai ChemPartner, where he established a comprehensive antibody R&D platform.  Prior to returning to China, Dr. Wu was a Volwiler Associate Fellow at Abbott Laboratories, where he led several novel biologics projects from concept to regulatory filing. Dr. Wu received his Ph.D. degree from the University of Georgia in the US, and postdoctoral fellowship at Harvard Medical School with a grant from the Cancer Research Institute.
查看详情>>
Richard WANG
Richard WANG
发布时间: 2020 - 11 - 26
点击次数: 0
Positions： CEO
Company： Fosun Kite Biotechnology Co., Ltd
个人简介：
waiting
查看详情>>
Baoping WANG
Baoping WANG
发布时间: 2020 - 11 - 26
点击次数: 0
Positions： COO
Company： Beijing Shenogen Pharma Group Ltd.
个人简介：
Dr. Wang is currently Chief Operating Office of Beijing Shenogen Pharma Group Ltd. And previously the President of Novo Nordisk Research Center China, the first R&D center set up by a global pharmaceutical company in China.  Baoping received a BS degree in Applied Chemistry from Shanghai Jiao Tong University in 1982, and a PhD in Genetics from University of Minnesota in 1990. He did his postdoc research at Harvard Medical School where he then served sequentially as an Instructor and Assistant Professor. His research area focused on molecular and cellular immunology. Baoping joined industry when he returned China in 1998 to head a health care group in Novo Nordisk China R&D center. In 2001, Novo Nordisk established a new R&D center based on the health care group, Baoping was the head of the center since its founding. From April 2007, Baoping also served as a Vice President of Novo Nordisk R&D, and from January 2011 through July 2018, as President of Novo Nordisk Research Center China. He has joined Beijing Shenogen Pharma Group Ltd. as Chief Operating Office from August 2018.
查看详情>>